Member Info for GeneralOz

With all this data available, it seems that Conifer aren’t taking anymore stock. They’ve reduced their position and have not increased during the last placing.

Even more concerning is the European Healthcare fund not triggering a TR1. Clearly they want to be able to sell stock without notifying PIs.

So Conifer and Baillie Gifford have sold out? Also it states that the principle place of operation is the United Kingdom. Does that imply that there is no operations taking place in the US?

Current significant shareholders are as follows:

Lombard Odier Investment Managers 3.3%

As at 30th April 2024 the company has 360,042,104 ordinary shares of 10p each in issue.

1.3% of the ordinary shares of the Company are not held in public hands.

Avacta Group has not applied or agreed to have any of its securities (including its AIM securities) admitted or traded on any other exchanges or trading platforms.

There are no restrictions on the transfer of Avacta Group plc’s AIM securities.

Avacta Group plc is subject to the UK City Code on Takeovers and Mergers.

Avacta Group plc is incorporated in the United Kingdom and its principal place of operation is the United Kingdom.

This information was last updated on 30th April 2024.

The recent placing barely covers the operating loss. So who's ready for the 20p placing to raise another 25m this time next year?

If they get rid of Smiffy and TG the share price will be off to the races. The overhang of these two is bigger than the placing itself.

As said by the CEO. How can it be so, when the share price is still sub 50p? Something has gone seriously wrong and PIs haven’t been told something.

… of death spirals.

TG is in cohort with the old boys and suits. He’s the reason for the death spiral finance. He lets the old boys join the party at their own price and takes advantage of long term holders.

Maybe we can get back to 60p plus

That’s a defeatist mentality, desperately hoping it will go back to 60p. For a stock that previously traded above 100p and was touted to be a paradigm shift. Just wow.

This is a company that should be trading below 20p. Even the bulls don’t believe it’ll get back to 60p.

NY holding hands with the management. Probably doesn’t want management to go as they give him inside information before normal shareholders.

The CEO carefully crafted his words. What has actually happened, is the company has actively tried to do some deals. Unfortunately nobody was interested and the deals that they were able to do were offered at such a low price it wouldn’t have been worthwhile.

The death spiral overhang and difficulties raising capital is like a dark cloud over this company.

GDR is a good example. That’s where this company is going. Good luck all

So Alastair if you really have sufficient data to partner the precision platform, why can’t you sign a big deal now?

Don’t have enough data? Or is the data that you have just not good enough? Something just doesn’t add up. Cue LFT.

Been there done that. Smiffy told everyone LFTs demand was going to outweigh supply for the foreseeable future. It turned out that there was no demand because the LFT didn’t work. He didn’t sell any and bring enough cash in.

How can we be sure AVA6000 will work? Why did Neil Bell leave so soon when he had experience of commercialisation?

Smiffy won't be hanging around much longer. He'll be selling shares so he can buy his new house, no doubt. His salary bump last year was to make his mortgage more affordable now there's high interest rates. Just a shame the company he runs is now more affordable.

Alastair valued each share at 120p with the LFT.

And the market continues to value each share at 50p (or 54p). Data not as good as it seems then?

If the CEO claims that it works unequivocally, then why can’t he get a license deal? He has always said his term sheets would be ready for a licence deal once he started to see that phase 1 data. So can’t he find anyone who’s interested? Or does it not work unequivocally?

As I’ve said before, the so called specialist healthcare fund is probably Ophidian’s SIPP. Nothing to boast about really for someone who equates Avacta to the scandalous British Biotech.

The real kicker is when the city boy said he focuses on whether the company meets its timelines. So now we know the high quality institutions will be majors sellers at any sign of lapse in timeline by the company.

We know the institutions get better visibility of this, so expect major sell offs when these institutions start selling. This is going to drop like a bomb once the market makers figure out what’s going on.

Those in the know sold up above 100p. They knew the company was in a distressed cash position. And just like in 2020, those that sold up at 200p knew the placing was coming at 120p.

That’s what happens when anyone gets too close to the truth around here.

Just when valuable discussion opens up, they get it deleted.

The bear case is too strong to ignore by those in the know.